<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00228943</url>
  </required_header>
  <id_info>
    <org_study_id>0501-03</org_study_id>
    <secondary_id>DOD-BC043199</secondary_id>
    <secondary_id>043199</secondary_id>
    <nct_id>NCT00228943</nct_id>
  </id_info>
  <brief_title>The Role of Serotonin in Hot Flashes After Breast Cancer</brief_title>
  <official_title>The Role of Serotonin in Hot Flashes After Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this proposal is to improve our understanding of the role of tryptophan and
      serotonin in hot flashes. The main hypothesis is that alterations in tryptophan and serotonin
      levels are involved in the induction of hot flashes in women with breast cancer and genetic
      variations in the serotonin receptors and transporters also play a role.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Among women with breast cancer, hot flashes are a frequent, severe and bothersome symptom.
      For this group, hot flashes are negatively related to mood, affect, and daily activities and
      can compromise compliance with life-saving medications (e.g., tamoxifen). Over 60% of breast
      cancer survivors report hot flashes, with 59% stating they are extremely severe and 44%
      reporting them to be extremely bothersome. Unfortunately, limitations in our understanding of
      hot flash physiology limit clinicians' abilities to fully treat this symptom. Although the
      current non-hormonal treatment of choice for hot flashes after breast cancer targets the
      central serotonin system (e.g., paroxetine, venlafaxine), the role of serotonin in hot
      flashes has not been directly tested. Because the effectiveness of these agents has been
      based largely on improvement in subjective reporting of hot flashes, it is not clear whether
      benefits are due to physiological effects on hot flashes or due to improvements in mood or
      other related symptoms. In addition, these and other currently available treatments are not
      acceptable, appropriate, or effective for all women with breast cancer. Understanding the
      physiological mechanisms involved in hot flashes after breast cancer will enable us to
      develop more targeted behavioral and/or pharmacological therapies to be used in lieu of, or
      in addition to, currently available therapies so that we can eradicate hot flashes and
      improve the quality of life for women with breast cancer.

      Results implicating direct effects of tryptophan and serotonin on objective hot flashes will
      help guide the development of improved interventions for alleviating hot flashes in women
      with breast cancer. These interventions may target the central serotonin system either
      behaviorally (e.g., diet) or pharmacologically (e.g., alternative drug therapeutics). If
      direct manipulation of tryptophan and serotonin does not affect hot flashes, these findings
      will be equally as useful in guiding future research on non-serotonin related etiologies and
      interventions. Findings from this study will ultimately be used to eradicate hot flashes as a
      frequent, severe and bothersome breast cancer treatment related condition, thereby, improving
      quality of life for all women with breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Tryptophan Levels</measure>
    <time_frame>baseline, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours</time_frame>
    <description>Mean serum tryptophan levels (blood draw) at the end of the nadir period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Subject Hot Flash Frequency</measure>
    <time_frame>One 24 hour monitoring session per week for 8 weeks</time_frame>
    <description>Mean of the 24 hour monitoring sessions for each patient based on one 24 hour monitoring session after each intervention using an electronic monitor.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Acute tryptophan depletion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Full-strength tryptophan depletion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Half-strength tryptophan depletion drink used as a control</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Acute tryptophan depletion</intervention_name>
    <description>L-alanine (5.5g), L-arginine (4.9g), L-cysteine (2.7g), glycine (3.2g), L-histidine (3.2g), L-isoleucine (8.0g), L-leucine (13.5g), L-lysine (11.0g), L-methionine (3.0g), L-phenylalanine (5.7g), L-proline (12.2g), L-serine (6.9g), L-threonine (6.9g), L-tyrosine (6.9g), L-valine (8.9g)</description>
    <arm_group_label>Acute tryptophan depletion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Half-strength tryptophan depletion (Control)</intervention_name>
    <description>L-alanine (1.4g), L-arginine (1.2g), L-cysteine (0.7g), glycine (0.8g), L-histidine (0.8g), L-isoleucine (2.0g), L-leucine (3.4g), L-lysine (2.8g), L-methionine (0.8g), L-phenylalanine (1.4g), L-proline (3.1g), L-serine (1.7g), L-threonine (1.7g), L-tyrosine (1.7g), L-valine (2.2g), and fillers (7.95g).</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Willing and able to provide informed consent

          -  Reporting daily hot flashes

          -  Able to read, write, and speak English

          -  Postmenopausal to limit sample variability (&gt; 12 months amenorrhea)

          -  Greater then 1 month but &lt; 5 years post-treatment (surgery, radiation, chemotherapy)
             for non-metastatic breast cancer.

          -  These criteria allow inclusion of women successfully treated for recurrent breast
             cancer since there is no known reason to exclude them. Menopausal status is assessed
             using self-reports due to problems in reliably measuring follicle-stimulating hormone
             levels and estradiol in tamoxifen users.

        Exclusion Criteria:

          -  Exclusion criteria are current depression, history of migraines or hepatitis, abnormal
             chemistry profile (e.g., sodium, potassium, glucose), or a positive urine drug screen
             for illegal substances.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet S Carpenter, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Carpenter JS, Yu M, Wu J, Von Ah D, Milata J, Otte JL, Johns S, Schneider B, Storniolo AM, Salomon R, Desta Z, Cao D, Jin Y, Philips S, Skaar TC. Evaluating the role of serotonin in hot flashes after breast cancer using acute tryptophan depletion. Menopause. 2009 Jul-Aug;16(4):644-52. doi: 10.1097/gme.0b013e318199e9f6.</citation>
    <PMID>19265726</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 27, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2005</study_first_posted>
  <results_first_submitted>November 13, 2008</results_first_submitted>
  <results_first_submitted_qc>December 8, 2008</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 10, 2008</results_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2015</last_update_posted>
  <responsible_party>
    <name_title>Janet Carpenter, PhD, RN</name_title>
    <organization>Indiana University School of Nursing</organization>
  </responsible_party>
  <keyword>Breast cancer survivorship</keyword>
  <keyword>Hot Flashes</keyword>
  <keyword>Serotonin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Serotonin</mesh_term>
    <mesh_term>Tryptophan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from a Midwestern outpatient cancer clinic from 2005 to 2007.</recruitment_details>
      <pre_assignment_details>260 women were screened, 39 of whom were not interested, 162 were found ineligible.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Full Strength Acute Tryptophan Depletion and Control</title>
          <description>Subjects were randomized to receive both a full-strength acute tryptophan depletion drink and half-strength tryptophan depletion drink (control). Some participants received the full-strength drink first for week 1 and then crossed-over to the half-strength (control) drink for week 2; the other participants received the half-strength (control) drink for week 1 and then crossed over to the full-strength drink for week 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Week 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Week 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Sample</title>
          <description>Consented subjects in the entire sample were randomized to one of two groups for the cross-over design study. One group of subjects received a full-strength tryptophan depletion drink during week 1 followed by a half-strength (control) drink week 2. The other group of subjects received a half-strength tryptophan depletion (control) drink during week 1 followed by a full-strength drink week 2.
The final analysis combined groups to compare full strength versus control.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.4" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Tryptophan Levels</title>
        <description>Mean serum tryptophan levels (blood draw) at the end of the nadir period.</description>
        <time_frame>baseline, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours</time_frame>
        <population>The number of subjects with complete serum data for both arms of the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Full Strength Acute Tryptophan Depletion</title>
          </group>
          <group group_id="O2">
            <title>Half-Strength Tryptophan Depletion - Control</title>
          </group>
        </group_list>
        <measure>
          <title>Serum Tryptophan Levels</title>
          <description>Mean serum tryptophan levels (blood draw) at the end of the nadir period.</description>
          <population>The number of subjects with complete serum data for both arms of the study were analyzed.</population>
          <units>nmol/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0034" spread=".0027"/>
                    <measurement group_id="O2" value="0.02" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective Subject Hot Flash Frequency</title>
        <description>Mean of the 24 hour monitoring sessions for each patient based on one 24 hour monitoring session after each intervention using an electronic monitor.</description>
        <time_frame>One 24 hour monitoring session per week for 8 weeks</time_frame>
        <population>Subjects with completed hot flash data during both arms of study.</population>
        <group_list>
          <group group_id="O1">
            <title>Full Strength Acute Tryptophan Depletion</title>
          </group>
          <group group_id="O2">
            <title>Half-Strength Tryptophan Depletion - Control</title>
          </group>
        </group_list>
        <measure>
          <title>Objective Subject Hot Flash Frequency</title>
          <description>Mean of the 24 hour monitoring sessions for each patient based on one 24 hour monitoring session after each intervention using an electronic monitor.</description>
          <population>Subjects with completed hot flash data during both arms of study.</population>
          <units>frequency of hot flashes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.30" spread="2.92"/>
                    <measurement group_id="O2" value="2.62" spread="3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Full Strength Acute Tryptophan Depletion</title>
          <description>No adverse events</description>
        </group>
        <group group_id="E2">
          <title>Half-Strength Tryptophan Depletion - Control</title>
          <description>No adverse events</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Janet S. Carpenter</name_or_title>
      <organization>Indiana University</organization>
      <phone>317-278-6093</phone>
      <email>carpentj@iupui.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

